PFE-360

• Description :

  PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo[1][2].

• Product Name Alternative :

  PF-06685360

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  LRRK2

• Type :

  Reference compound

• Related Pathways :

  Autophagy

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/pfe-360.html

• Purity :

  99.48

• Solubility :

  DMSO : 10.42 mg/mL (ultrasonic)

• Smiles :

  N#CC1=CC(C2=CNC3=NC=NC(N4CCOCC4)=C32)=CN1C

• Molecular Formula :

  C16H16N6O

• Molecular Weight :

  308.34

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Marco A.S. Baptista, et al. LRRK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal Accumulation of Lamellar Bodies in Type II Pneumocytes in Non-Human Primates but are Reversible and Without Pulmonary Functional Consequences.|[2]Andersen MA, et al. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation. Neurobiol Dis. 2018 Aug;116:13-27.|[3]Andersen MA, et al. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018 Feb 15;395:15-22.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1527475-61-1]